| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 167-175, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
J Lukas, S Groshen, B Saffari, N Niu, A Reles, WH Wen, J Felix, LA Jones, FL Hall and MF Press
Department of Pathology, University of Southern California School of Medicine, Los Angeles 90033, USA.
The p53 gene is altered in approximately 50% of human cancers and is considered to be important in the pathogenesis of these malignancies. The p53 protein product regulates the transition from G1 to S phase of the cell cycle and entry to the DNA damage repair pathway. As alterations in this pathway appear to be important in a variety of human cancers, downstream effector proteins of p53 are potential sites for somatic alterations. WAF1/Cip1, also known as WAF1, Cip1, sdi1, or CAP20, codes for a 21-kd protein (p21WAF1/Cip1), which was recently described as a universal inhibitor of cyclins and is thus critical in cell cycle control. Mutations in WAF1/Cip1 are potentially important in human malignancies because they could affect the control of the cell cycle. To understand whether mutations of WAF1/Cip1 occur in cancer, we screened 53 cases of invasive breast carcinoma, 35 cases of ductal carcinoma in situ (DCIS), 53 ovarian carcinomas, and 47 endometrial carcinomas in the second exon of WAF1/Cip1 (90% of the open reading frame). p21WAF1/Cip1 expression was characterized with immunohistochemistry. Cells from the blood of 21 normal individuals were also characterized using single-strand conformational polymorphism analysis, DNA sequencing and restriction analysis. Single-strand conformational polymorphism analysis demonstrated an altered mobility pattern for exon 2 in 12 invasive breast cancers (22.6%), 5 DCIS of the breast (14%), 8 invasive ovarian carcinomas (15%), and 9 endometrial carcinomas (19%). In total, 209 samples were screened, and 38 cases (18.2%) had an altered codon 31. Each case with altered single-strand conformational polymorphism, analyzed by DNA sequencing and/or restriction analysis, showed the same alteration of codon 31, a C to A transversion encoding a change in amino acid sequence from serine to arginine (31Ser-->31Arg). DNA from the blood of 21 normal individuals showed the same alteration in WAF1/Cip1 in 4 cases (19%). Furthermore, paired normal tissue was available for 3 of 20 breast carcinomas with the Ser31Arg transversion. Normal DNA from all 3 cases showed the same 31Arg alteration as found in the tumor tissue. These results indicate that codon 31 is a polymorphic site and that the serine to arginine shift is a polymorphism. p21WAF1/Cip1 expression, identified by immunohistochemistry, was found to vary in a pattern that depended both on the tissue type and on the presence or absence of the codon 31 polymorphism. Using pair-wise comparisons in breast DCIS, we found higher protein expression in tumor nuclei as compared with benign stromal cell nuclei (P = 0.002) or normal ductal epithelium (P = 0.005). Invasive breast cancer specimens showed a trend in p21WAF1/Cip1 immunostaining similar to DCIS but did not reach statistical significance (P = 0.12). However, when cases with extensive desmoplastic reaction were excluded, a statistically significant association (P = 0.019) similar to that in DCIS was noted. In contrast to the breast tumors, ovarian carcinomas exhibited significantly greater p21WAF1/Cip1 expression in the benign stromal (fibroblast) nuclei surrounding the tumor than in the carcinoma cell nuclei (P = 0.016). Endometrial carcinoma revealed no difference in staining when comparing benign tissue with carcinoma (P = 0.99); however, unlike breast and ovarian carcinomas in which there was no correlation between p21WAF1/Cip1 expression and the presence or absence of the alteration at the 31st codon, endometrial carcinomas showed an increased percentage of immunopositive nuclei associated (P = 0.056) with 31Arg. These results demonstrate tissue-specific expression patterns of WAF1/Cip1 in different tumors which appears to be characteristic of the tumor type.
This article has been cited by other articles:
 |
|
 |
|
  K. E. Driver, H. Song, F. Lesueur, S. Ahmed, N. L. Barbosa-Morais, J. P. Tyrer, B. A.J. Ponder, D. F. Easton, P. D.P. Pharoah, A. M. Dunning, et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population Carcinogenesis, February 1, 2008; 29(2): 333 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Healy, H. Belanger, P. Beaulieu, M. Lariviere, D. Labuda, and D. Sinnett Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia Blood, January 15, 2007; 109(2): 683 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, Z. Liu, E. M. Sturgis, Q. Shi, R. M. Chamberlain, M. R. Spitz, and Q. Wei Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck Carcinogenesis, September 1, 2005; 26(9): 1596 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Xi, K.-Y. Ding, X.-L. Su, D.-F. Chen, W.-C. You, Y. Shen, and Y. Ke p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions Carcinogenesis, November 1, 2004; 25(11): 2201 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kibel, B. K. Suarez, J. Belani, J. Oh, R. Webster, M. Brophy-Ebbers, C. Guo, W. J. Catalona, J. Picus, and P. J. Goodfellow CDKN1A and CDKN1B Polymorphisms and Risk of Advanced Prostate Carcinoma Cancer Res., May 1, 2003; 63(9): 2033 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Powell, I. L. van Staveren, P. Roosken, F. Grieu, E. M.J.J. Berns, and B. Iacopetta Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer Carcinogenesis, February 1, 2002; 23(2): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Keshava, B. L. Frye, M. S. Wolff, E. C. McCanlies, and A. Weston Waf-1 (p21) and p53 Polymorphisms in Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 127 - 130. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Lukas, N. Niu, and M. F. Press p53 Mutations and Expression in Breast Carcinoma in Situ Am. J. Pathol., January 1, 2000; 156(1): 183 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Baekelandt, R. Holm, C. G. Trope, J. M. Nesland, and G. B. Kristensen Lack of Independent Prognostic Significance of p21 and p27 Expression in Advanced Ovarian Cancer: An Immunohistochemical Study Clin. Cancer Res., October 1, 1999; 5(10): 2848 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation Endocr. Rev., August 1, 1999; 20(4): 501 - 534. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
